This clinical trial is focused on studying the effects of a new treatment for atopic dermatitis, a condition that causes the skin to become red, itchy, and inflamed. The treatment being tested is called amlitelimab, which is given as an injection under the skin. Amlitelimab is a type of protein known as a monoclonal antibody, which is designed to target specific parts of the immune system that may be involved in causing atopic dermatitis. The study will also involve the use of a placebo, which is a substance with no active medication, to compare the effects of amlitelimab.

The purpose of this study is to evaluate how effective and safe amlitelimab is for people aged 12 and older who have moderate-to-severe atopic dermatitis. Participants will continue using their regular topical treatments, such as corticosteroids, during the study. The trial will last for about 24 weeks, during which participants will receive injections of either amlitelimab or a placebo. The study will monitor changes in the severity of the skin condition and any side effects experienced by the participants.

In addition to amlitelimab, the study will also consider the effects of other treatments like tacrolimus and pimecrolimus, which are commonly used topical medications for atopic dermatitis. These treatments are applied directly to the skin and work by reducing inflammation and suppressing the immune response. The study aims to provide more information on how amlitelimab compares to these existing treatments in managing atopic dermatitis symptoms.